← Back to Search

CAR T-cell Therapy

OriCAR-017 for Multiple Myeloma

Phase 1
Research Sponsored by OriCell Therapeutics Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights


This trial is the first study conducted by Oricell Therapeutics Inc. in the United States. It aims to assess the safety, how the body processes the drug, how the drug works in the

Who is the study for?
This trial is for adults aged 18-75 with relapsed/refractory multiple myeloma, who have tried at least three prior treatments and are refractory to the last one. They must meet specific criteria based on their type of myeloma protein levels and have a life expectancy over 12 weeks.Check my eligibility
What is being tested?
The RIGEL Study is testing OriCAR-017, an anti-GPRC5D cell product by Oricell Therapeutics Inc., focusing on its safety, how it's processed in the body (PK/PD), and initial effectiveness in treating multiple myeloma patients.See study design
What are the potential side effects?
While specific side effects for OriCAR-017 aren't listed here, similar therapies may cause immune reactions, infusion-related symptoms, fatigue, blood count changes, increased infection risk, and potential impact on organ function.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose-limiting toxicity (DLT)
Maximum tolerated dose (MTD) of OriCAR-017 US-P1
Secondary outcome measures
Assessment of Clinical Benefit Rate (CBR)
Assessment of Disease Control Rate (DCR)
Assessment of Duration of Response (DOR) of treatment in patients with RR/MM
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: OriCAR-017Experimental Treatment1 Intervention
Single OriCAR-017 infusion

Find a Location

Who is running the clinical trial?

OriCell Therapeutics Co., Ltd.Lead Sponsor
3 Previous Clinical Trials
203 Total Patients Enrolled
~54 spots leftby Dec 2026